Nuclidium

Headquarter
Basel, Switzerland

Milestones
Founded: 2017
Invested: 2025

CO-Founder and CEO
Leila Jaafar Ph.D

Vertical
Biotech

Board Participation
Regina Hodits, Board Member

Website

Linkedin

 

 

Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis.

Related news:

Angelini Ventures co-leads €84 Million Series B investment in NUCLIDIUM's revolutionary cancer theranostic platform